In our study of 309 affected BRCA1/2 and PALB2 carriers with operable breast cancer, the receipt of chemotherapy following an index breast cancer diagnosis was 70% overall but varied from 57% in BRCA2 carriers to upwards of 80% in BRCA1 and PALB2 carriers. This evidence concerns the gene BRCA1 and breast carcinoma.